Annals of Surgical Oncology

, Volume 26, Issue 12, pp 3939–3944 | Cite as

Saving the Male Breast: A Systematic Literature Review of Breast-Conservation Surgery for Male Breast Cancer

  • L. M. De La CruzEmail author
  • P. T. R. Thiruchelvam
  • J. Shivani
  • J. Trina
  • S. A. Blankenship
  • C. S. Fisher
Breast Oncology



Male breast cancer (MBC) management is extrapolated from female BC. Mastectomy remains the most frequently used surgical procedure for male breast cancer (MBC). We performed a literature review to assess the use of breast-conservation (BCS) in MBC as well as outcomes following BCS.


A systematic literature was performed, and articles screened to identify studies that measured overall survival (OS), disease-free survival (DFS), or local recurrence (LR) in patients undergoing BCS. Weighted averages based on study size were performed for LR, DFS, and 5-year OS.


Eight studies met the inclusion criteria with male breast surgery cases, and 859 (14.7%) underwent BCS. The mean follow-up time was 53 months, and mean age was 62.6 years, with stage II as the most common presentation. Two studies reported that 50–71.4% of patients underwent sentinel lymph node biopsy, and four studies reported axillary lymph node dissection in 14.3–100%. Five studies reported on adjuvant radiation therapy in 12.0–100% of total patients undergoing BCS. Four studies reported use of hormonal therapy in 73.8–100% of patients. Four studies reported use of chemotherapy in 25–66.7% of patients. Seven studies reported LR among 116 patients, with a weighted average of 9.9%. Three studies reported on DFS in 14 patients, with a weighted average 85.6%. Two studies report OS in 143 patients with a weighted average of 84.4%.


Breast conservation may be considered a safe alternative in the surgical treatment of MBC. Future research should focus on better standardization of local therapy for MBC and improved reporting of outcomes.


Author’s Contribution

L.C., C.F., and P.T. conceptualized and designed the project. L.C., S.J., and T.J. performed data acquisition. S.B. performed data analysis. L.C. performed interpretation and drafted the initial manuscript. L.C., C.F., S.J., T.J., and P.T. assisted in critical revision of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.


No external funding was secured for this study. The authors have no financial relationships or conflicts of interest relevant to this article to disclose.


  1. 1.
  2. 2.
    Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115:429–30.CrossRefGoogle Scholar
  3. 3.
    Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85:629–39.CrossRefGoogle Scholar
  4. 4.
    Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A:1960–4.CrossRefGoogle Scholar
  5. 5.
    Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males: a report of 335 cases. Cancer. 1993;71:154–61.CrossRefGoogle Scholar
  6. 6.
    American Cancer Society. Cancer facts & figures 2018. Atlanta: American Cancer Society; 2018.Google Scholar
  7. 7.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark NN. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. Engl J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  8. 8.
    Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int J Radiat Oncol Biol Phys. 1986;12(5):717–20.CrossRefGoogle Scholar
  9. 9.
    Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H. EORTC—breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012; 13(4):412–9.CrossRefGoogle Scholar
  10. 10.
    De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J, Fisher CS. Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. Ann Surg Oncol. 2016;23(10):3247–58. Scholar
  11. 11.
    Romanoff A, Zabor EC, Stempel M, Sacchini V, Pusic A, Morrow M. A Comparison of patient-reported outcomes after nipple-sparing mastectomy and conventional mastectomy with reconstruction. Ann Surg Oncol. 2018;25(10):2909–16. Scholar
  12. 12.
    Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983–2009. Ann Surg Oncol. 2013;20(5):1545–50.CrossRefGoogle Scholar
  13. 13.
    Günhan-Bilgen I, Bozkaya H, Ustün E. Male breast disease: clinical, mammographic, and ultrasonographic features. Eur J Radiol. 2002;43(3):246–55.CrossRefGoogle Scholar
  14. 14.
    Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast. 2012;21(3):296–302. Scholar
  15. 15.
    Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, de Lara CT, Edeline J, Penault-Llorca F, Romestaing P, Delva C, Comet B, Belkacemi Y. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol. 2010;73(3):246–54. Scholar
  16. 16.
    Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, Resbeut M, Graic Y, Campana F, Moncho-Bernier V, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A(12):1960–4.CrossRefGoogle Scholar
  17. 17.
    Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast. 2007;16(6):653–6.CrossRefGoogle Scholar
  18. 18.
    Selcukbiricik F, Tural D, Aydoğan F, Beşe N, Büyükünal E, Serdengeçti S. Male breast cancer: 37-year data study at a single experience center in Turkey. J Breast Cancer. 2013;16(1):60–5. Scholar
  19. 19.
    Serarslan A, Gursel B, Okumus NO, Meydan D, Sullu Y, Gonullu G. Male breast cancer: 20 years experience of a tertiary hospital from the Middle Black Sea Region of Turkey. Asian Pac J Cancer Prev. 2015;16(15):6673–9.CrossRefGoogle Scholar
  20. 20.
    Yildirim E, Berberoğlu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24(6):548–52.CrossRefGoogle Scholar
  21. 21.
    Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer: bigger is not better. N Engl J Med. 2012;367:79–82.CrossRefGoogle Scholar
  22. 22.
    Cardoso F, Bartlett JMS, Slaets L.Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17. Scholar
  23. 23.
    Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT. Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: a population-based study. Eur J Cancer 2017;71:7–14.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • L. M. De La Cruz
    • 1
    Email author
  • P. T. R. Thiruchelvam
    • 2
  • J. Shivani
    • 3
  • J. Trina
    • 3
  • S. A. Blankenship
    • 4
  • C. S. Fisher
    • 5
  1. 1.Department of SurgeryINOVA Health System, Shar Cancer InstituteFAIRFAXUSA
  2. 2.Department of Cancer and SurgeryImperial CollegeLondonUK
  3. 3.Department of SurgeryImperial College HealthcareLondonUK
  4. 4.Department of Obstetrics and GynecologyWashington University in St. Louis School of MedicineSt. LouisUSA
  5. 5.Department of SurgeryIndiana University School of MedicineIndianapolisUSA

Personalised recommendations